



FinVector at ESGCT Annual Congress 2015, Helsinki

FinVector will be at booth 28/29 Stop by and talk with our European representatives about how we can partner with you for your manufacturing viral vector needs.

Speeches:

"Clinical Bio-Manufacturing Facility" by COO, QP Robert Shaw (on Thursday 17th at 09:30-10:45)

"Large-scale Vector Production" by Research Director, PhD (Molecular Medicine) Hanna P. Lesch (on Thursday 17th at 09:30-11:30)

"Bioprocessing of Cell & Gene Therapy Products" by Hanna P. Lesch (on Sunday 20th at 09:00-11:00)

Posters:

"Flow cytometry analysis for a recombinant adenoviral gene therapy vector" (P245) by Scientist, MSc (Biochemistry) Sara Paulo

"Development of large-scale downstream purification process for recombinant adenoviruses" (TBA) by Senior Manufacturing Development Scientist, PhD (Molecular Medicine) Outi Rautsi

"Scaling up adenovirus production in suspension and adherent processes, from bench top to clinics" (P153) by Senior Scientist, PhD (Biotechnology) Pia Valonen

"Development of potency assay for recombinant adenoviral gene therapy product (rAd-IFN) to treat intravesical non-muscle invasive bladder cancer" (P223)

by Head of analytical development MSc (Biochemistry) Jenni Mykkänen

Chairs:

"Regulatory Issues"-session S5c on Saturday 19th at 17:00-19:00 Analytical Director, LPhD (Molecular Genetics) **Minna Hassinen**

Use the opportunity and Visit FVT's State of the Art Research, Development and cGMP Manufacturing Site while in Finland!

To arrange a visit at our site in Kuopio during Your ESGT Congress, please complete the "Contact Us"-Form on our Web-Page.